Stock data
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN) reported net income of -US$103.69M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$119.66M | -US$103.69M | — |
| 2024 | — | — | -US$104.55M | -US$89.02M | — |
| 2023 | — | — | -US$83.53M | -US$71.58M | — |
| 2022 | — | — | -US$38.79M | -US$37.66M | — |
| 2021 | — | — | -US$51.44M | -US$51.38M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$32.48M | — |
| 2026-03-31 | — | -US$23.63M | — |
| 2025-12-31 | — | -US$29.67M | — |
| 2025-09-30 | — | -US$20.15M | — |
| 2025-06-30 | — | -US$25.34M | — |
| 2025-03-31 | — | -US$28.54M | — |
| 2024-12-31 | — | -US$23.18M | — |
| 2024-09-30 | — | -US$23.16M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.